| mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0053 |
0.9 |
| mRNA |
cediranib |
CTRPv2 |
pan-cancer |
AAC |
0.0083 |
0.9 |
| mRNA |
tandutinib |
CTRPv2 |
pan-cancer |
AAC |
0.0055 |
0.9 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0053 |
0.9 |
| mRNA |
BRD-K41597374 |
CTRPv2 |
pan-cancer |
AAC |
-0.005 |
0.9 |
| mRNA |
BRD1812 |
CTRPv2 |
pan-cancer |
AAC |
-0.0049 |
0.9 |
| mRNA |
masitinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0049 |
0.9 |
| mRNA |
AA-COCF3 |
CTRPv2 |
pan-cancer |
AAC |
0.0047 |
0.9 |
| mRNA |
PRIMA-1-Met |
CTRPv2 |
pan-cancer |
AAC |
-0.0067 |
0.9 |
| mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
-0.0043 |
0.9 |